Biotech Therapeutics
Biotech Therapeutics groups companies that discover and develop drug candidates using biologics, gene and cell therapies, RNA platforms, and specialty small molecules. Capital flows to this theme because scientific advances, regulatory support for rare and unmet indications, and deal activity with large pharmaceutical firms create high potential upside for clinical-stage successes.
1D-0.2%
1W+4.7%
1M-7.3%
3M+17.4%
6M+23.3%
1Y+161.6%
60 of 126 stocks are in a Stage 2 uptrend.
Equal-weighted index · 1 year+161.6%
Stocks in this theme
| Ticker | Price | 1M | 3M | 1Y | Stage | Trend | vs 52w high |
|---|---|---|---|---|---|---|---|
| IOVAIovance Biotherapeutics, Inc. | $14.82 | +81.4% | +273.3% | +599.1% | Stage 2 (extended) | 7/7 | 0% |
| MRNAModerna, Inc. | $192.57 | +37.2% | +165.6% | +660.2% | Stage 2 (extended) | 7/7 | -5.35% |
| KODKodiak Sciences Inc. | $94.8 | +153.8% | +154.6% | +499.6% | Stage 2 (extended) | 7/7 | 0% |
| ABCLAbCellera Biologics Inc. | $14.59 | +27.1% | +92.0% | +207.8% | Stage 2 (extended) | 7/7 | -1.55% |
| PGENPrecigen, Inc. | $8.56 | +23.5% | +63.0% | +135.8% | Stage 2 (extended) | 7/7 | 0% |
| AMLXAmylyx Pharmaceuticals, Inc. | $29.1 | -13.8% | +62.1% | +95.3% | Stage 2 (extended) | 6/7 | -26.63% |
| HALOHalozyme Therapeutics, Inc. | $110.4 | +3.7% | +43.4% | +50.6% | Stage 2 (extended) | 7/7 | -4.18% |
| ZLABZai Lab Ltd | $26.34 | +3.5% | +37.5% | -16.7% | Stage 2 (continuation) | 7/7 | -23.52% |
| HCMHUTCHMED (China) Ltd | $14.63 | +20.7% | +35.7% | -6.6% | Stage 3 | 4/7 | -10.74% |
| CORTCorcept Therapeutics Inc | $115.23 | +1.7% | +30.2% | +37.3% | Stage 2 (extended) | 7/7 | -6.75% |
| TARSTarsus Pharmaceuticals, Inc. | $78.61 | +5.9% | +29.1% | +35.4% | Stage 3 | 6/7 | -13.41% |
| GMABGenmab A/S | $35.67 | +7.6% | +29.1% | +21.6% | Stage 3 | 6/7 | 0% |
| ONCBeOne Medicines Ltd. | $365.94 | +1.8% | +25.9% | +9.9% | Stage 3 | 6/7 | -3.05% |
| BHCBausch Health Companies Inc. | $5.83 | -8.5% | +22.2% | -9.9% | Stage 3 | 4/7 | -26.2% |
| REGNRegeneron Pharmaceuticals, Inc. | $758.27 | -5.1% | +21.4% | +35.2% | Stage 3 | 6/7 | -11% |
| PFEPfizer Inc | $28.52 | +0.2% | +19.4% | +20.0% | Stage 3 | 6/7 | -1.72% |
| BLTEBelite Bio, Inc | $169.82 | +9.1% | +19.3% | +132.6% | Stage 3 | 6/7 | -12.29% |
| KNSAKiniksa Pharmaceuticals International, plc | $74.61 | -5.1% | +18.6% | +92.4% | Stage 2 (continuation) | 7/7 | -7.8% |
| GILDGilead Sciences, Inc. | $149.05 | +1.9% | +18.3% | +32.4% | Stage 2 (re-acceleration) | 7/7 | -4.33% |
| SMMTSummit Therapeutics Inc. | $16.91 | +24.2% | +17.6% | -19.3% | Stage 1 | 3/7 | -35.9% |
| AMGNAmgen Inc | $421.51 | -1.9% | +16.7% | +53.9% | Stage 2 (continuation) | 7/7 | -5.09% |
| ADMAAdma Biologics, Inc. | $10.03 | +6.8% | +16.5% | -31.8% | Stage 1 | 2/7 | -50.79% |
| MRKMerck & Co., Inc. | $145.31 | -1.7% | +15.9% | +84.9% | Stage 2 (continuation) | 7/7 | -7.12% |
| TAKTakeda Pharmaceutical Co Ltd | $18.19 | +1.2% | +13.5% | +24.2% | Stage 2 (re-acceleration) | 7/7 | -4.51% |
| PTGXProtagonist Therapeutics, Inc | $140.89 | -4.6% | +12.6% | +116.3% | Stage 2 (continuation) | 7/7 | -11.18% |
| VRDNViridian Therapeutics, Inc.\DE | $20.59 | -11.1% | +12.1% | +2.0% | Stage 3 | 2/7 | -39.05% |
| BMYBristol Myers Squibb Co | $62.4 | -6.6% | +10.6% | +41.3% | Stage 1 | 7/7 | -8.36% |
| VTRSViatris Inc | $17.72 | +7.3% | +9.5% | +86.7% | Stage 2 (continuation) | 7/7 | -3.01% |
| RVMDRevolution Medicines, Inc. | $205.26 | -0.1% | +9.5% | +345.5% | Stage 2 (continuation) | 7/7 | -7.19% |
| HRMYHarmony Biosciences Holdings, Inc. | $39.26 | -0.3% | +9.1% | +42.0% | Stage 2 (continuation) | 6/7 | -8.4% |
| EXELExelixis, Inc. | $58.41 | +6.9% | +8.3% | +44.0% | Stage 2 (continuation) | 7/7 | -1.22% |
| BIIBBiogen Inc. | $225.88 | +4.3% | +7.7% | +63.1% | Stage 2 (continuation) | 7/7 | -1.23% |
| URGNUroGen Pharma Ltd. | $40.63 | -5.7% | +7.1% | +112.3% | Stage 2 (continuation) | 7/7 | -19.21% |
| INSMINSMED Inc | $114.14 | -6.3% | +6.7% | -19.4% | Stage 4 | 0/7 | -46.01% |
| INCYIncyte Corp | $121.35 | -1.5% | +6.6% | +44.6% | Stage 2 (continuation) | 7/7 | -6.6% |
| IDYAIDEAYA Biosciences, Inc. | $38.42 | -4.2% | +6.2% | +41.3% | Stage 1 | 6/7 | -9.56% |
| ARGXArgenx Se | $958.91 | -7.0% | +5.4% | +33.4% | Stage 2 (continuation) | 7/7 | -9.44% |
| VRTXVertex Pharmaceuticals Inc / Ma | $522.81 | -4.0% | +5.0% | +32.3% | Stage 2 (continuation) | 7/7 | -6.3% |
| MBXMBX Biosciences, Inc. | $58.62 | -4.8% | +4.8% | +226.8% | Stage 2 (continuation) | 7/7 | -17.09% |
| BNTXBioNTech SE | $98.3 | -3.3% | +4.7% | +0.2% | Stage 1 | 4/7 | -17.63% |
| TVTXTravere Therapeutics, Inc. | $58.88 | -11.2% | +4.5% | +144.9% | Stage 2 (continuation) | 7/7 | -12.8% |
| ROIVRoivant Sciences Ltd. | $36.57 | +5.6% | +4.4% | +142.2% | Stage 2 (continuation) | 7/7 | -12.53% |
| TGTXTg Therapeutics, Inc. | $55.78 | +2.7% | +4.2% | +51.5% | Stage 2 (continuation) | 7/7 | -5.55% |
| ABBVAbbVie Inc. | $261.59 | +2.0% | +4.2% | +17.2% | Stage 2 (continuation) | 7/7 | -1.76% |
| MESOMesoblast Ltd | $14.65 | -12.6% | +4.0% | -8.6% | Stage 4 | 0/7 | -30.1% |
| BMRNBiomarin Pharmaceutical Inc | $60 | -8.0% | +3.8% | +11.1% | Stage 2 (continuation) | 6/7 | -14.58% |
| EWTXEdgewise Therapeutics, Inc. | $40.6 | -2.8% | +3.7% | +157.8% | Stage 2 (continuation) | 7/7 | -16.03% |
| NUVBNuvation Bio Inc. | $5.6 | -15.9% | +3.3% | +73.9% | Stage 3 | 3/7 | -41.3% |
| GRFSGrifols SA | $7.31 | -5.3% | +3.3% | -25.1% | Stage 4 | 0/7 | -27.05% |
| ZYMEZymeworks Inc. | $26.49 | -9.9% | +3.0% | +59.6% | Stage 2 (re-acceleration) | 7/7 | -14.69% |
| IBRXImmunityBio, Inc. | $9.44 | +18.7% | +2.6% | +277.6% | Stage 2 (extended) | 7/7 | -18.27% |
| AUPHAurinia Pharmaceuticals Inc. | $16.2 | +0.5% | +2.5% | +46.4% | Stage 2 (re-acceleration) | 7/7 | -13.02% |
| ARQTArcutis Biotherapeutics, Inc. | $26.43 | +10.3% | +2.3% | +41.9% | Stage 3 | 5/7 | -15.29% |
| OGNOrganon & Co. | $13.7 | -0.5% | +1.9% | +32.2% | Stage 2 (continuation) | 7/7 | -0.58% |
| RLAYRelay Therapeutics, Inc. | $18.05 | -1.8% | +1.6% | +247.8% | Stage 1 | 7/7 | -13.01% |
| SYRESpyre Therapeutics, Inc. | $89.03 | -0.3% | +0.2% | +444.2% | Stage 2 (continuation) | 7/7 | -18.26% |
| LGNDLigand Pharmaceuticals Inc | $312.37 | +9.9% | +0.1% | +84.0% | Stage 2 (continuation) | 7/7 | -3.17% |
| SRPTSarepta Therapeutics, Inc. | $18.22 | -13.4% | +0.1% | -3.2% | Stage 3 | 1/7 | -25.48% |
| IMNMImmunome Inc. | $21.51 | -21.5% | +0.1% | +89.7% | Stage 1 | 4/7 | -27.88% |
| CGONCG Oncology, Inc. | $70.89 | -5.7% | +0.0% | +81.4% | Stage 2 (re-acceleration) | 7/7 | -12.13% |
| PVLAPalvella Therapeutics, Inc. | $137.93 | -9.6% | -0.2% | +121.6% | Stage 2 (continuation) | 7/7 | -12.77% |
| NRIXNurix Therapeutics, Inc. | $23.71 | -8.0% | -0.8% | +155.5% | Stage 2 (continuation) | 7/7 | -14.68% |
| SNYSanofi | $41.23 | -7.1% | -1.0% | -9.7% | Stage 4 | 1/7 | -21.23% |
| UTHRUNITED THERAPEUTICS Corp | $541.89 | +6.2% | -1.0% | +27.7% | Stage 2 (re-acceleration) | 6/7 | -9.19% |
| MDGLMadrigal Pharmaceuticals, Inc. | $503.96 | -6.7% | -2.0% | +13.7% | Stage 3 | 2/7 | -16.4% |
| KYMRKymera Therapeutics, Inc. | $111.79 | -5.9% | -2.1% | +91.1% | Stage 2 (continuation) | 7/7 | -12.19% |
| PCVXVaxcyte, Inc. | $56.9 | -6.3% | -2.1% | +67.5% | Stage 2 (re-acceleration) | 7/7 | -10.11% |
| DNTHDianthus Therapeutics, Inc. /DE/ | $88.05 | -16.6% | -2.4% | +122.6% | Stage 1 | 6/7 | -24.07% |
| JAZZJazz Pharmaceuticals plc | $231.52 | -7.6% | -2.5% | +79.5% | Stage 2 (continuation) | 7/7 | -11.51% |
| ZBIOZenas BioPharma, Inc. | $26.97 | -16.6% | -3.7% | +31.1% | Stage 2 (continuation) | 4/7 | -37.53% |
| NKTRNektar Therapeutics | $60.55 | -15.2% | -6.0% | +2.8% | Stage 1 | 3/7 | -39.66% |
| ELVNEnliven Therapeutics, Inc. | $45.84 | -20.8% | -6.0% | +125.8% | Stage 2 (re-acceleration) | 6/7 | -25.04% |
| GSKGSK plc | $48.17 | -4.1% | -6.1% | +17.2% | Stage 1 | 2/7 | -21.27% |
| MLYSMineralys Therapeutics, Inc. | $25.13 | -2.1% | -6.5% | -36.1% | Stage 4 | 0/7 | -46.9% |
| PHVSPharvaris N.V. | $31.72 | -8.3% | -6.6% | +31.3% | Stage 2 (continuation) | 7/7 | -18.37% |
| TLXTelix Pharmaceuticals Ltd | $10.97 | -1.1% | -7.3% | +10.9% | Stage 2 (continuation) | 7/7 | -14.5% |
| SUPNSupernus Pharmaceuticals, Inc. | $43.04 | -1.6% | -7.5% | -8.5% | Stage 4 | 1/7 | -24.49% |
| NVSNovartis Ag | $142.57 | -6.2% | -7.5% | +14.9% | Stage 1 | 3/7 | -15.45% |
| SRRKScholar Rock Holding Corp | $48.32 | -14.9% | -8.6% | +26.0% | Stage 1 | 5/7 | -19.52% |
| PRAXPraxis Precision Medicines, Inc. | $291.23 | -16.9% | -8.9% | +456.0% | Stage 1 | 5/7 | -24.62% |
| KRYSKrystal Biotech, Inc. | $332.56 | -7.5% | -10.5% | +88.2% | Stage 2 (continuation) | 7/7 | -12.06% |
| RCUSArcus Biosciences, Inc. | $25.83 | -11.8% | -10.7% | +93.9% | Stage 2 (re-acceleration) | 7/7 | -18.18% |
| ORKAOruka Therapeutics, Inc. | $83.29 | -10.1% | -10.7% | +331.8% | Stage 2 (continuation) | 6/7 | -26.34% |
| INDVIndivior Pharmaceuticals, Inc. | $35.85 | +2.6% | -10.9% | +48.8% | Stage 1 | 6/7 | -14.3% |
| VCELVericel Corp | $40.14 | +0.6% | -11.1% | +26.3% | Stage 1 | 7/7 | -16.91% |
| IMVTImmunovant, Inc. | $33.78 | -17.3% | -11.4% | +110.3% | Stage 2 (re-acceleration) | 7/7 | -24.87% |
| BBIOBridgeBio Pharma, Inc. | $65.8 | -14.1% | -11.7% | +26.6% | Stage 1 | 2/7 | -27.03% |
| CLDXCelldex Therapeutics, Inc. | $32.41 | -18.2% | -11.9% | +24.0% | Stage 1 | 5/7 | -27.77% |
| AZNAstrazeneca PLC | $161.47 | -0.4% | -12.2% | +9.5% | Stage 4 | 1/7 | -22.92% |
| DFTXDefinium Therapeutics, Inc. | $38.06 | -4.2% | -12.3% | +256.7% | Stage 2 (continuation) | 7/7 | -21.44% |
| IRONDisc Medicine, Inc. | $65.46 | -16.8% | -12.7% | +0.6% | Stage 4 | 1/7 | -30.44% |
| TNGXTango Therapeutics, Inc. | $24.95 | +9.2% | -13.2% | +192.5% | Stage 2 (re-acceleration) | 7/7 | -24.16% |
| BCRXBiocryst Pharmaceuticals Inc | $8.33 | -14.1% | -13.7% | +8.9% | Stage 1 | 4/7 | -25.02% |
| RAPPRapport Therapeutics, Inc. | $33.6 | -31.0% | -14.7% | +20.1% | Stage 1 | 4/7 | -36% |
| ASNDAscendis Pharma A/S | $227.83 | -13.4% | -14.9% | +18.9% | Stage 1 | 4/7 | -17.8% |
| BHVNBiohaven Ltd. | $13.35 | -12.6% | -15.3% | -8.9% | Stage 2 (continuation) | 6/7 | -26.28% |
| NBIXNeurocrine Biosciences Inc | $141.84 | -7.9% | -15.5% | +1.1% | Stage 1 | 4/7 | -23.54% |
| SLSSELLAS Life Sciences Group, Inc. | $12.31 | -6.8% | -16.6% | +664.6% | Stage 2 (extended) | 7/7 | -20.38% |
| COGTCogent Biosciences, Inc. | $32.02 | -8.5% | -16.8% | +126.6% | Stage 1 | 1/7 | -25.26% |
| ERASErasca, Inc. | $14.66 | -18.0% | -18.2% | +709.9% | Stage 1 | 5/7 | -34.76% |
| ALNYAlnylam Pharmaceuticals, Inc. | $246.74 | +2.5% | -18.2% | -44.9% | Stage 4 | 0/7 | -49.77% |
| ARWRArrowhead Pharmaceuticals, Inc. | $65.45 | -20.6% | -18.6% | +93.8% | Stage 1 | 4/7 | -26.94% |
| TRVITrevi Therapeutics, Inc. | $14.32 | -13.7% | -18.7% | +60.0% | Stage 1 | 5/7 | -26.56% |
| OCULOcular Therapeutix, Inc | $7.67 | -26.9% | -19.0% | -37.3% | Stage 4 | 1/7 | -52.39% |
| ACADAcadia Pharmaceuticals Inc | $20.15 | -30.3% | -20.0% | -5.5% | Stage 1 | 2/7 | -34.09% |
| PTCTPtc Therapeutics, Inc. | $64.78 | -6.8% | -20.4% | +6.8% | Stage 4 | 0/7 | -27.66% |
| DNLIDenali Therapeutics Inc. | $20.67 | -13.0% | -20.4% | +48.2% | Stage 1 | 5/7 | -24.04% |
| STOKStoke Therapeutics, Inc. | $26 | -16.7% | -20.5% | +5.1% | Stage 4 | 0/7 | -32.2% |
| NBTXNanobiotix S.A. | $31.16 | -23.3% | -21.1% | +72.9% | Stage 1 | 4/7 | -43.42% |
| ALKSAlkermes plc. | $40.52 | -13.8% | -21.7% | +45.3% | Stage 1 | 5/7 | -26.62% |
| RGCRegencell Bioscience Holdings Ltd | $6.22 | +12.9% | -22.5% | -62.0% | Stage 4 | 1/7 | -88.24% |
| CYTKCytokinetics Inc | $65.91 | -7.0% | -22.7% | +22.3% | Stage 1 | 4/7 | -24.47% |
| AXSMAxsome Therapeutics, Inc. | $184.39 | -7.1% | -23.4% | +56.8% | Stage 1 | 4/7 | -27.74% |
| CELCCelcuity Inc. | $79.52 | -10.7% | -23.9% | +52.7% | Stage 4 | 1/7 | -45.15% |
| VERAVera Therapeutics, Inc. | $32.29 | -5.3% | -24.3% | +11.7% | Stage 4 | 1/7 | -42% |
| ABVXAbivax S.A. | $99.02 | -11.4% | -25.3% | +18.8% | Stage 1 | 1/7 | -31.86% |
| DYNDyne Therapeutics, Inc. | $16.11 | -36.6% | -26.1% | +30.2% | Stage 1 | 2/7 | -39.84% |
| NAMSNewAmsterdam Pharma Co N.V. | $24.32 | -4.0% | -28.2% | -7.5% | Stage 4 | 0/7 | -41.33% |
| MIRMMirum Pharmaceuticals, Inc. | $85.48 | -12.8% | -29.0% | +17.3% | Stage 1 | 3/7 | -33.51% |
| LEGNLegend Biotech Corp | $19.89 | -4.3% | -33.5% | -39.5% | Stage 1 | 1/7 | -45.18% |
| XENEXenon Pharmaceuticals Inc. | $37.19 | -38.2% | -38.3% | -4.8% | Stage 1 | 3/7 | -47.59% |
| IONSIonis Pharmaceuticals Inc | $44.65 | -26.0% | -43.6% | -30.4% | Stage 4 | 0/7 | -48.38% |
| QUREuniQure N.V. | $24.16 | -50.4% | -46.5% | -59.3% | Stage 1 | 4/7 | -65.77% |
| RAREUltragenyx Pharmaceutical Inc. | $15.03 | -40.4% | -53.6% | -50.5% | Stage 4 | 0/7 | -58.87% |
| LQDALiquidia Corp | $30.26 | -55.6% | -61.9% | +32.7% | Stage 1 | 4/7 | -66.76% |
| ALMSAlumis Inc. | $7.39 | -66.1% | -72.3% | +87.1% | Stage 1 | 3/7 | -75.61% |
Deep dive
This theme covers firms focused on therapeutic innovation rather than broad healthcare services. Included names range from platform builders that create delivery or discovery tools to clinical-stage developers pursuing treatments for oncology, rare genetic disorders, neurological conditions, and immunologic diseases. Examples span mRNA and vaccine platforms, antibody discovery and engineering, gene and cell therapy developers, RNA-targeting companies, and traditional small-molecule biopharma.
Demand for biotech therapeutics comes from several concrete drivers. Scientific advances in mRNA chemistry, viral vectors, antibody engineering, and targeted small molecules lower the technical barriers to new modalities. Continued unmet medical need in oncology, rare disease, and chronic conditions creates a market for differentiated therapies, while regulatory pathways and incentives for orphan and breakthrough-designated programs shorten time to market for some candidates. Partnerships, licensing deals, and acquisitions by large pharmaceutical firms move capital into companies that hold promising science or platforms.
The value chain splits into distinct roles. Discovery and platform companies build tools and libraries that accelerate target identification and antibody or cell engineering; AbCellera, Relay, and computational drug-discovery firms fit this role. Small and mid-size biotech companies focus on preclinical work and early-stage clinical trials where clinical data define value; examples include firms pursuing novel small molecules, biologics, or cell therapies. Platform developers and manufacturers address delivery and scale-up challenges — mRNA and viral-vector specialists illustrate this need — while large pharmaceutical companies typically take on late-stage development, regulatory filing, commercialization, and global distribution.
Whether the theme continues to attract capital depends on clinical results, regulatory decisions, and the commercial environment. Positive trial outcomes and clear safety profiles lead to licensing deals, acquisitions, and commercialization, while late-stage failures or safety concerns reduce investor interest. Manufacturing scale-up and supply reliability matter for modalities that require complex production. Payers and pricing decisions shape commercial return after approval, and intellectual property plus partner arrangements influence how value transfers across the sector.
Stock of the Day picks in this theme
GMABGenmab A/SGenmab is emerging as a Biotech Therapeutics leader as sustained institutional accumulation and strong relative strength have pushed shares near a 52-week high in a confirmed uptrend.Sep 27ARGXArgenx SeArgenx's validated Stage 1→2 breakout, reclaimed 200-day trend, and substantial institutional ownership position it as a timely technical leader within Biotech Therapeutics with improving relative strength.Sep 21ROIVRoivant Sciences Ltd.Roivant is a technically leading, institutionally held biotech whose stock has outperformed the market while near-term revenue and GAAP EPS remain weak and volatile.Sep 14KNSAKiniksa Pharmaceuticals International, plcKiniksa is a mid-cap therapeutics company showing sustained double-digit quarterly revenue growth, improving GAAP profitability, and strong relative strength versus the S&P 500 as a theme leader.Sep 11PTGXProtagonist Therapeutics, IncProtagonist Therapeutics is a biotech therapeutics leader trading in an established uptrend with strong relative strength, intermittent GAAP profitability, and a recovering revenue run-rate that merits watching.Sep 9TGTXTg Therapeutics, Inc.Tg Therapeutics has shifted to commercial growth, with quarterly revenue rising from $63.5M in 2024Q1 to $240.3M in 2026Q2 and substantial institutional sponsorship.Sep 7ARWRArrowhead Pharmaceuticals, Inc.Arrowhead has moved into material reported revenue and improving GAAP diluted EPS while trading in an established uptrend with heavy institutional ownership and strong relative strength.Sep 6EXELExelixis, Inc.Exelixis pairs steady mid-teens revenue growth and rising GAAP diluted EPS with a confirmed Stage‑2 technical uptrend and strong relative strength within oncology therapeutics.Sep 5KRYSKrystal Biotech, Inc.Krystal Biotech is a commercial-stage gene therapy company that grew quarterly revenue from $8.6M to $119.2M while delivering consecutive GAAP profits, positioning it as a timely leader in dermatology biotech.Sep 4ACADAcadia Pharmaceuticals IncAcadia shows steady mid-single- to mid-teens revenue growth, heavy institutional sponsorship, and a validated Stage 1→2 breakout, positioning it as a timely leader in Biotech Therapeutics.Sep 2HRMYHarmony Biosciences Holdings, Inc.Harmony Biosciences shows durable revenue and GAAP profit gains, with Q2 2026 revenue +30% YoY and GAAP diluted EPS +88% YoY, making it a timely specialty-biotech leader.Aug 30